Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01043939 · ClinicalTrials.gov registry record · Phase 1

Purple Grape Juice in Improving Vascular Health in Childhood Cancer Survivors

A Phase 1 study, sponsored by University of Minnesota.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target

NCT01043939 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01043939, a Phase 1 study, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target

Study Summary

Rationale: Survivors of childhood cancer are at an increased risk of developing cardiovascular risk factors as well as early cardiovascular disease, likely due to the intensive therapeutic regimen used to treat their cancer. Purple grape juice (PGJ) is a rich source of flavonoids and a powerful antioxidant. Clinical studies in both diseased and healthy adults suggest that daily consumption of PGJ contributes to increased antioxidant capacity, reduced low-density lipoprotein (LDL) oxidation, and improved vasodilation. Purpose: This randomized clinical trial is evaluating whether purple grape juice can reduce oxidative stress and improve the vascular health of survivors of childhood cancer in the early stages of cardiovascular disease.

Interventions

  • OTHER Apple Juice
  • OTHER Purple Grape Juice

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2009-11
Est. Completion 2010-12
Phase Phase 1

Sponsor

University of Minnesota

966 total trials

What the Registry Record Tells You About NCT01043939

The ClinicalTrials.gov registry entry for NCT01043939 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Apple Juice is the first listed.

NCT01043939 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01043939 about?

NCT01043939 is a clinical study titled "Purple Grape Juice in Improving Vascular Health in Childhood Cancer Survivors". Rationale: Survivors of childhood cancer are at an increased risk of developing cardiovascular risk factors as well as early cardiovascular disease, likely due to the intensive therapeutic regimen used to treat their cancer. Purple grape juice (PGJ) is a rich source of flavonoids and a powerful anti...

What is the current status of trial NCT01043939?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-11. Estimated completion is 2010-12.

What interventions are being tested in trial NCT01043939?

The interventions under investigation include: Apple Juice (OTHER), Purple Grape Juice (OTHER).

Who is sponsoring clinical trial NCT01043939?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.